Atrophy Clinical Trials

256 recruitingLast updated: June 18, 2026

There are 256 actively recruiting atrophy clinical trials across 55 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Dallas, Texas, United States, New York, New York, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Atrophy Trials at a Glance

256 actively recruiting trials for atrophy are listed on ClinicalTrialsFinder across 6 cities in 55 countries. The largest study group is Not Applicable with 87 trials, with the heaviest enrollment activity in Dallas, New York, and Boston. Lead sponsors running atrophy studies include Vanderbilt University Medical Center, Hoffmann-La Roche, and Biogen.

Treatments under study

About Atrophy Clinical Trials

Looking for clinical trials for Atrophy? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Atrophy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Atrophy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 256 trials

Recruiting

Clinical Procedures to Support Research in ALS

Amyotrophic Lateral SclerosisPrimary Lateral SclerosisProgressive Muscular Atrophy+1 more
University of Miami1,200 enrolled11 locationsNCT03489278
Recruiting
Not Applicable

Postoperative Electrical Muscle Stimulation Two

Colorectal, CancerSurgeryMuscle Atrophy+1 more
University of Nottingham45 enrolled1 locationNCT06964438
Recruiting
Phase 1

Phase 1 Study of C.001 in Retinal Degeneration

Geographic AtrophyAge-Related Macular DegenerationStargardt Disease+1 more
Cellio Therapeutics Inc15 enrolled1 locationNCT07594236
Recruiting
Not Applicable

VRehab-SMA Phase 1.2

Spinal Muscular Atrophy (SMA)
University of Oxford12 enrolled1 locationNCT07578454
Recruiting

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Geographic AtrophyMacular Degeneration
Astellas Pharma Global Development, Inc.500 enrolled65 locationsNCT06779773
Recruiting

Natural History Study of Synucleinopathies

Multiple System AtrophyParkinson DiseaseDementia With Lewy Bodies+5 more
NYU Langone Health800 enrolled8 locationsNCT01799915
Recruiting
Phase 2

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

Multiple System Atrophy
Teva Branded Pharmaceutical Products R&D LLC350 enrolled58 locationsNCT06568237
Recruiting
Phase 2

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

Multiple System Atrophy
Teva Branded Pharmaceutical Products R&D LLC200 enrolled26 locationsNCT07197866
Recruiting

Prospective Multicenter Registry Study of Multiple System Atrophy in China

Multiple System AtrophyParkinson's DiseaseAtypical Parkinsonism
Peking University First Hospital214 enrolled1 locationNCT07644013
Recruiting
Phase 2

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

Multiple System Atrophy
Tiziana Life Sciences LTD5 enrolled1 locationNCT06868628
Recruiting
Early Phase 1

Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies

Parkinson DiseaseHealthy AdultMultiple System Atrophy (MSA)
MODAG GmbH13 enrolled1 locationNCT07640555
Recruiting
Phase 2

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Geographic Atrophy secondary to Age Related Macular Degeneration
Novartis Pharmaceuticals272 enrolled28 locationsNCT07441642
Recruiting

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

Geographic Atrophy secondary to Age Related Macular Degeneration
Complement Therapeutics75 enrolled12 locationsNCT07144137
Recruiting
Phase 4

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

Muscular Atrophy, Spinal
Hoffmann-La Roche28 enrolled19 locationsNCT05861999
Recruiting
Phase 3

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

Muscular Atrophy, Spinal
Biogen30 enrolled4 locationsNCT07221669
Recruiting
Phase 2

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Geographic AtrophyMacular Degeneration
Janssen Research & Development, LLC274 enrolled104 locationsNCT06635148
Recruiting
Phase 2

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Geographic Atrophy secondary to Age Related Macular Degeneration
Apellis Pharmaceuticals, Inc.240 enrolled68 locationsNCT07215390
Recruiting
Not Applicable

Graftless TSFE Via Self-tapping Implants

Alveolar Bone AtrophyEdentulous Posterior MaxillaMaxillary Sinus Pneumatization
Sana'a University20 enrolled1 locationNCT07424742
Recruiting

Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders

MyoclonusNeurological RegressionCherry Red Spot+1 more
National Human Genome Research Institute (NHGRI)200 enrolled1 locationNCT00029965
Recruiting
Phase 1

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

Geographic Atrophy (GA)
Regeneron Pharmaceuticals54 enrolled7 locationsNCT07230834